News | June 25, 2024
Sun Pharma completes Taro merger
Combined entity is better positioned to compete in increasingly competitive generics industry
Combined entity is better positioned to compete in increasingly competitive generics industry
HaystackAnalytics is engaged in the business of developing genomic analysis software
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
Sun Pharma's Dadra facility receives OAI status from US FDA
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of USD 15 million in the U.S.
This recognition attests to Sun Pharma’s commitment to incorporate Environmental, Social, and Governance (ESG) principles through focused initiatives across its businesses
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Subscribe To Our Newsletter & Stay Updated
